J Drug Target. 2025 Mar 10:1-19. doi: 10.1080/1061186X.2025.2477077. Online ahead of print.
ABSTRACT
Esophageal cancer (EC) is among the most common illnesses globally, and its prognosis is unfavorable. Surgery, radiotherapy, and chemotherapy are the primary therapy options for EC. Despite the occasional efficacy of these traditional treatment modalities, individuals with EC remain at a significant risk for local recurrence and metastasis. Consequently, innovative and efficacious medicines are required. In recent decades, clinical practice has effectively implemented cell therapy, which includes both stem cell and non-stem cell-based approaches, as an innovative tumor treatment, offering renewed hope to patients with esophageal squamous cell carcinoma (ESCC). This paper examines the theoretical framework and contemporary advancements in cell treatment for individuals with EC. We further described current clinical studies and summarized essential data related to survival and safety assessments.
PMID:40063049 | DOI:10.1080/1061186X.2025.2477077
